MAPT and Alzheimer disease: Inhibition of IL-1 signaling reduces several tau kinases including GSK-3β, and p38–MAPK, and phosphorylated tau levels as well as expression of S100B, a marker of inflammatory A1 astrocyte in the brain of AD mice (Kitazawa et al., 2011).